|
ANDAs Short on QbD Should Sit in 180-Day Review Queue, New OGD MAPP States
ANDAs that lack basic quality-by-design (QbD) elements will be categorized as requiring “major” amendments and more extensive FDA consideration, according to a new Manual of Policies and Procedures (MAPP) for reviewers in CDER’s Office of Generic Drugs (OGD).
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives